Of the 12 patients in the 200mg* cohort of VX-135, one patient dropped out because of an SAE and one patient completed treatment but relapsed or didn’t respond to treatment.
The data from the 100mg cohort of VX-135 are worse (see press release). I stand by the assertion in #msg-90498491.
*FDA has a clinical hold on the 200mg dose of VX-135.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.